Epigenetic modifications: novel therapeutic strategies for systemic sclerosis?

References

• Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann. Rheum. Dis.66(7), 940–944 (2007).
   PubMed Web of Science ®Google Scholar
• Rubin LJ. Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future. Rheum. Dis. Clin. North Am.34(1), 191–197; VIII (2008).
   PubMed Web of Science ®Google Scholar
• Chung L, Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun. Rev.5(2), 125–128 (2006).
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Distler JH, Distler O. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. Curr. Rheumatol. Rep.13(1), 21–27 (2011).
   PubMedGoogle Scholar
• Distler JH, Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann. Rheum. Dis.69(Suppl. 1), i48–i51 (2010).
   Web of Science ®Google Scholar
• Distler JH, Distler O. Criteria to select molecular targets for anti-fibrotic therapy. Rheumatology (Oxford)47(Suppl. 5), v12–v13 (2008).
   Google Scholar
• Horn A, Distler JH. Vascular alterations upon activation of TGFβ signaling in fibroblasts – implications for systemic sclerosis. Arthritis Res. Ther.12(3), 125 (2010).
   PubMed Web of Science ®Google Scholar
• Beyer C, Distler JH, Distler O. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss Med. Wkly140, w13050 (2010).
   PubMed Web of Science ®Google Scholar
• Probst AV, Dunleavy E, Almouzni G. Epigenetic inheritance during the cell cycle. Nat. Rev. Mol. Cell Biol.10(3), 192–206 (2009).
   PubMed Web of Science ®Google Scholar
• Bronner C, Chataigneau T, Schini-Kerth VB, Landry Y. The “epigenetic code replication machinery”, ECREM: a promising drugable target of the epigenetic cell memory. Curr. Med. Chem.14(25), 2629–2641 (2007).
   PubMed Web of Science ®Google Scholar
• Maciejewska-Rodrigues H, Jüngel A, Gay R, Gay S. Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis. Mol. Immunol.47(1), 12–18 (2009).
   PubMedGoogle Scholar
• Corpet A, Almouzni G. Making copies of chromatin: the challenge of nucleosomal organization and epigenetic information. Trends Cell Biol.19(1), 29–41 (2009).
   PubMed Web of Science ®Google Scholar
• Huber LC, Brock M, Hemmatazad H et al. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum.56(4), 1087–1093 (2007).
   PubMed Web of Science ®Google Scholar
• Grabiec AM, Tak PP, Reedquist KA. Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on? Arthritis Res. Ther.10(5), 226 (2008).
   PubMed Web of Science ®Google Scholar
• Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell Mol. Life Sci.58(5–6), 728–736 (2001).
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet.37(4), 391–400 (2005).
   PubMed Web of Science ®Google Scholar
• Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet.10(1), 32–42 (2009).
   PubMed Web of Science ®Google Scholar
• Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett.280(2), 168–176 (2009).
   PubMed Web of Science ®Google Scholar
• Hemmatazad H, Maciejewska-Rodrigues HM, Maurer B et al. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum.60(5), 1519–1529 (2009).
   PubMed Web of Science ®Google Scholar
• Sequeira J, Boily G, Bazinet S et al.sirt1-null mice develop an autoimmune-like condition. Exp. Cell Res.314(16), 3069–3074 (2008).
   PubMed Web of Science ®Google Scholar
• Marks PA, Rifkind RA, Richon VM, Breslow R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin. Cancer Res.7(4), 759–760 (2001).
   PubMed Web of Science ®Google Scholar
• Butler KV, Kozikowski AP. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr. Pharm. Des14(6), 505–528 (2008).
   PubMed Web of Science ®Google Scholar
• Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett.280(2), 211–221 (2009).
   PubMed Web of Science ®Google Scholar
• Itoh Y, Suzuki T, Miyata N. Isoform-selective histone deacetylase inhibitors. Curr. Pharm. Des14(6), 529–544 (2008).
   PubMed Web of Science ®Google Scholar
• Monneret C. Histone deacetylase inhibitors. Eur. J. Med. Chem.40(1), 1–13 (2005).
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res.5(10), 981–989 (2007).
   PubMed Web of Science ®Google Scholar
• Rombouts K, Niki T, Wielant A, Hellemans K, Geerts A. Trichostatin A, lead compound for development of antifibrogenic drugs. Acta Gastroenterol. Belg.64(3), 239–246 (2001).
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum.54(7), 2271–2279 (2006).
   PubMed Web of Science ®Google Scholar
• Huber LC, Distler JH, Moritz F et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum.56(8), 2755–2764 (2007).
   PubMed Web of Science ®Google Scholar
• Olaharski AJ, Ji Z, Woo JY et al. The histone deacetylase inhibitor trichostatin a has genotoxic effects in human lymphoblasts in vitro. Toxicol. Sci.93(2), 341–347 (2006).
   PubMedGoogle Scholar
• Vanhaecke T, Papeleu P, Elaut G, Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr. Med. Chem.11(12), 1629–1643 (2004).
   PubMed Web of Science ®Google Scholar
• Elaut G, Torok G, Vinken M et al. Major Phase I biotransformation pathways of Trichostatin a in rat hepatocytes and in rat and human liver microsomes. Drug Metab. Dispos.30(12), 1320–1328 (2002).
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Perez G, Xu W et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol. Cancer Ther.6(9), 2525–2534 (2007).
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen C, Finger SN et al. SAHA – a potential epigenetic therapeutic agent for lung fibrosis? Eur. Respir. J. (2009).
   Google Scholar
• Mottet D, Bellahcene A, Pirotte S et al. Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ. Res.101(12), 1237–1246 (2007).
   PubMedGoogle Scholar
• Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell126(2), 321–334 (2006).
   PubMed Web of Science ®Google Scholar
• Ellis L, Pili R. Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel)3(8), 2411–2469 (2010).
   PubMedGoogle Scholar
• Urbich C, Rossig L, Kaluza D et al. HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. Blood113(22), 5669–5679 (2009).
   PubMed Web of Science ®Google Scholar
• Li Y, Sawalha AH, Lu Q. Aberrant DNA methylation in skin diseases. J. Dermatol. Sci.54(3), 143–149 (2009).
   PubMedGoogle Scholar
• Karouzakis E, Gay RE, Gay S, Neidhart M. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat. Rev. Rheumatol.5(5), 266–272 (2009).
   PubMed Web of Science ®Google Scholar
• Espada J, Esteller M. Epigenetic control of nuclear architecture. Cell Mol. Life Sci.64(4), 449–457 (2007).
   PubMedGoogle Scholar
• Flotho C, Claus R, Batz C et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia23(6), 1019–1028 (2009).
   PubMed Web of Science ®Google Scholar
• Brueckner B, Kuck D, Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J.13(1), 17–22 (2007).
   PubMed Web of Science ®Google Scholar
• Dees C, Akhmetshina A, Busch N et al. Inhibitors of DNA methyltransferases exert potent anti-fibrotic effects via re-activation of socs-3. Ann. Rheum Dis.68(Suppl. 3), 94 (2009).
   PubMedGoogle Scholar
• Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics. FEBS J.278(10), 1598–1609 (2011).
   PubMed Web of Science ®Google Scholar
• Fabbri M, Garzon R, Cimmino A et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl Acad. Sci. USA104(40), 15805–15810 (2007).
   PubMed Web of Science ®Google Scholar
• Lambova S, Muller-Ladner U. Pulmonary arterial hypertension in systemic sclerosis. Autoimmun. Rev.9(11), 761–770 (2010).
   PubMedGoogle Scholar